Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102388 | 0.73 | TSHR (0.35) | — | |
| SCHEMBL4135633 | 0.73 | ALDH1A1 (0.46) | CYP1A2CYP1B1 | |
| SCHEMBL2799483 | 0.70 | NPC1 (0.36) | — | |
| SCHEMBL669872 | 0.69 | ALDH1A1 (0.50) | CA1CA9STSCYP2B6CYP1A2 | |
| SCHEMBL22915707 | 0.67 | STS (0.44) | CA1CA9STSCYP2B6CYP1A2 | |
| SCHEMBL30718843 | 0.66 | ERN1 (0.41) | — | |
| SCHEMBL26927730 | 0.66 | ALDH1A1 (0.50) | CA1CA9STSCYP2B6CYP1A2 | |
| SCHEMBL2930385 | 0.66 | ERN1 (0.41) | — | |
| SCHEMBL7784298 | 0.65 | STS (0.37) | CA1CA9STSCYP2B6 | |
| SCHEMBL586277 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595994-B1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-8759523-B2 | Process for preparing pyrano—[2,3-C]pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| EP-2595994-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | Glaxo Group Limited (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | GLAXO GROUP LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2012012391-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | DHPS, AKR1C3, Q6ZSR9 | CA1 1817/4885CA9 985/4885STS 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.